SLC5A2 and type 2 diabetes mellitus: The initial event, an immediate dip of the GFR caused by a reduction of intraglomerular pressure in response to the restoration of the tubuloglomerular feedback mechanism (Vallon and Thomson, 2020), was reported for the SGLT2 inhibitor dapagliflozin (Heerspink et al., 2021; Jhund et al., 2021), canagliflozin (Perkovic et al., 2019) and empagliflozin (Wanner et al., 2016; Wanner et al., 2018) in cardiovascular patients with type II diabetes.